Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
Tao Jiang(Tongji University), Shengxiang Ren(Tongji University), Luonan Chen(ShanghaiTech University), Helong Zhang(Air Force Medical University), Caicun Zhou(Tongji University), Yanqiu Zhao(Henan Cancer Hospital), Yanjun Xu(Guangzhou Center for Disease Control and Prevention), Jianying Zhou(Zhejiang University), Renhua Guo(Jiangsu Province Hospital), Sheng Yao(National University of Singapore), Jiarui Wu(Beijing University of Chinese Medicine), Yongqian Shu(Jiangsu Province Hospital), Yalei Zhang(Tongji University), Jie Zhang(Tongji University), Ningqiang Ma(Air Force Medical University), Linhong Deng(Changzhou University), Zhang Bao(First Affiliated Hospital Zhejiang University), Yun Fan(Zhejiang Cancer Hospital), Jianxing He(Southern Medical University), Hong Wang(Chinese PLA General Hospital), Guanghui Gao(Tongji University), Xiaoqing Liu(Chinese PLA General Hospital), Hui Feng(Nanjing University of Chinese Medicine), Xiaoqian Mu(Henan Cancer Hospital), Pingyang Wang(Center for Excellence in Molecular Cell Science)
Cited by 94
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504